MOYOM Biotech获得国泰资本融资，加速再生医美领域的全球扩张-动脉网

MOYOM Biotech Secures Financing from Cathay Capital to Accelerate Global Growth in Regenerative Aesthetics

CISION 等信源发布 2026-09-28 17:42



可切换为仅中文







SHANGHAI

上海

，

Sept. 28, 2026

2026年9月28日

/PRNewswire/ -- MOYOM Biotech, a biotechnology company specializing in regenerative aesthetic biomaterials, today announced that it has completed a new financing round from the

/美通社/ -- 专注于再生医美生物材料的生物科技公司MOYOM Biotech今日宣布，已完成新一轮融资，投资方为

Cathay Consumer Co-Creation Fund

国泰消费者共创基金

, managed by

，由...管理

Cathay Capital

国泰资本

. The investment marks an important milestone in the company's development and will support its next phase of global growth.

此次投资标志着公司发展的重要里程碑，并将支持其下一阶段的全球扩张。

继续阅读

Cathay Capital

国泰资本

Aphranel® MagiCCrystal Novo: Three Dimensions of Regenerative Aesthetics — Immediate Shaping, Evolving Regeneration and Controlled Degradation. Beauty Exists Across Time. Shape • Regenerate • Evolve.

Aphranel® MagiCCrystal Novo：再生美学的三个维度——即时塑形、渐进再生与可控降解。美，跨越时间存在。塑形 • 再生 • 进化。

The fund was jointly established by

该基金由……共同设立

Cathay Capital, L'Oréal

国泰资本，欧莱雅

and the

和

Shanghai Jing'an District Government

上海市静安区人民政府

to foster innovation in beauty, health and skin science. Cathay Capital has built a global investment ecosystem spanning consumer, healthcare and technology, with notable investments including Moonshot AI (Kimi), autonomous driving company Momenta, U.S.

旨在促进美容、健康及皮肤科学领域的创新。凯辉资本已构建起一个横跨消费、医疗健康和科技领域的全球投资生态系统，其知名投资项目包括月之暗面（Kimi）、自动驾驶公司Momenta以及美国

fintech

金融科技

company Chime,

Chime 公司

digital asset

数字资产

platform Ledger, global delivery platform Glovo and AI biotechnology company Owkin.

平台 Ledger、全球配送平台 Glovo 以及人工智能生物技术公司 Owkin。

In addition to identifying emerging brands, investment platforms of this kind can give strategic partners earlier access to emerging technologies, supply-chain capabilities and innovation in adjacent industries. Cathay Capital's investment in MOYOM reflects growing interest in technologies and biomaterial innovations with the potential to shape the next generation of the beauty and medical aesthetics industry..

除了识别新兴品牌，此类投资平台还能让战略合作伙伴更早地接触新兴技术、供应链能力以及相邻行业的创新。国泰资本对MOYOM的投资，反映了市场对那些有望塑造下一代美容与医美行业的技术和生物材料创新的兴趣日益增长。

Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly

MOYOM成立于2018年，专注于纳米医用生物材料及三类可吸收植入医疗器械，尤其是

calcium hydroxylapatite (CaHA)

羟基磷灰石钙（CaHA）

regenerative materials. Its flagship brand,

再生材料。其旗舰品牌，

Aphranel

阿芙拉内尔

, brings MOYOM's proprietary biomaterials research to market. Positioned as a

，将MOYOM专有的生物材料研究成果推向市场。定位为

new-generation CaHA biostructurer

新一代CaHA生物结构剂

, Aphranel

，阿芙拉内尔

is designed to combine immediate structural support, regenerative stimulation and

旨在结合即时结构支撑、再生刺激和

complete biodegradation

完全生物降解

。

MOYOM's technology platform is built around two proprietary technologies: ACD-MT

MOYOM 的技术平台围绕两项专有技术构建：ACD-MT

raspberry-shaped through-hole CaHA microspheres and PCD-ETT

覆盆子状通孔羟基磷灰石微球与聚碳酸酯二醇-乙撑硫脲

physically cross-linked CMC gel technology. Together, they are engineered to deliver structural performance, support regenerative interaction and enable controlled biodegradation.

物理交联羧甲基纤维素（CMC）凝胶技术。二者协同设计，旨在提供结构性能，支持再生性相互作用，并实现可控生物降解。

Aphranel

阿弗拉内尔

received

已收到

Class III medical device registration

第三类医疗器械注册

from China's

来自中国的

National Medical Products Administration (NMPA)

国家药品监督管理局（NMPA）

in February 2025 and

2025年2月，并

certification under the European Union Medical Device Regulation (EU MDR)

欧盟医疗器械法规（EU MDR）认证

in May 2026

2026年5月

, establishing a regulatory foundation for international expansion. Since its commercial launch in May 2025, Aphranel

，为国际扩张奠定监管基础。自2025年5月商业发布以来，Aphranel

has been introduced in more than

已在超过

700 medical aesthetics clinics across China

中国700家医疗美容诊所

, demonstrating increasing market adoption alongside continued scientific and regulatory progress.

，显示出随着科学和监管方面的持续进展，市场接受度不断提高。

With its proprietary technology platform, key regulatory milestones and growing market presence, MOYOM is entering a new phase of growth. Leveraging Cathay Capital's global ecosystem, the company plans to accelerate

凭借专有技术平台、关键监管里程碑以及不断扩大的市场影响力，MOYOM 正迈入新的增长阶段。借助凯辉资本的全球生态系统，该公司计划加速

clinical translation, pursue additional regulatory approvals and expand into overseas markets

临床转化，寻求额外的监管批准，并拓展海外市场

, while continuing to invest in next-generation regenerative biomaterials.

，同时继续投资下一代再生生物材料。

The financing will support MOYOM's efforts to bring

这笔融资将支持MOYOM致力于实现

biomaterial innovation

生物材料创新

originating in China to international markets and establish Aphranel

源自中国，面向国际市场，并建立 Aphranel

as a science-driven regenerative aesthetics brand with global reach.